Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | DBH | P09172 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | LPO | P22079 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976953 | 0.81 | ALDH1A1 (0.33) | ALDH1A1MAPTPOLBKDM4ENAPRT | |
| SCHEMBL28132698 | 0.79 | MAP2K1 (0.35) | ALDH1A1MAPTPOLBNAPRTKMT2A | |
| SCHEMBL28497933 | 0.78 | ALDH1A1 (0.36) | ALDH1A1MAPTPOLBMMP2 | |
| SCHEMBL11582763 | 0.78 | SIGMAR1 (0.36) | ALDH1A1MAPTPOLBMMP2MEN1 | |
| SCHEMBL2111851 | 0.72 | — | — | |
| SCHEMBL8943286 | 0.71 | TP53 (0.35) | ALDH1A1MAPTPOLBMMP2TP53 | |
| Cadaverine Tartrate SCHEMBL28777753 | 0.68 | ALDH1A1 (0.43) | ALDH1A1MAPTPOLBMEN1LMNA | |
| SCHEMBL28413087 | 0.68 | ALDH1A1 (0.37) | ALDH1A1MAPTPOLBMMP2DBH | |
| SCHEMBL28021089 | 0.68 | — | — | |
| SCHEMBL28021092 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11092461-A | — | — | None | — | — | JP | disclosed |
| JP-10001473-A | — | — | None | — | — | JP | disclosed |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4051287-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | Otonomy, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114845721-A | Otic formulations for drug-induced ototoxicity | 奥德纳米有限公司 | 2022-08-02 | — | — | CN | disclosed |
| WO-2021087408-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTONOMY, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-0896043-B1 | Adhesive | TOKUYAMA CORP (JP) | 2002-10-23 | — | — | EP | disclosed |
| EP-0802194-B1 | Novel thiouracil derivatives and metal surface-treating agent comprising thereof | TOKUYAMA CORP (JP) | 2002-06-19 | — | — | EP | disclosed |
| US-6133338-A | TYPIFIED BY 6-METHACRYLOYLOXYHEXYL 2-THIOURACIL-5-CARBOXYLATE, A RADICAL-POLYMERIZABLE MONOMER, AND A POLYMERIZATION INITIATOR; DENTAL ADHESIVE; GOOD ADHESIVENESS TO NOBLE METALS AND ALLOYS THEREOF | TOKUYAMA CORPORATION (JP) | 2000-10-17 | — | — | US | disclosed |
| JP-H1192461-A | DISULFIDE COMPOUND AND METAL SURFACE TREATING AGENT | TOKUYAMA CORP | 1999-04-06 | — | — | JP | disclosed |
| EP-0896043-A1 | Adhesive | TOKUYAMA CORPORATION (JP) | 1999-02-10 | — | — | EP | disclosed |
| US-5795497-A | Thiouracil derivatives and metal surface-treating agent comprising thereof | TOKUYAMA CORPORATION (JP) | 1998-08-18 | — | — | US | disclosed |
| JP-H101473-A | THIOURACIL DERIVATIVE | TOKUYAMA CORP | 1998-01-06 | — | — | JP | disclosed |
| EP-0802194-A2 | Novel thiouracil derivatives and metal surface-treating agent comprising thereof | TOKUYAMA CORPORATION (JP) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTC, SLC26A4, OAT | ALDH1A1 121/4885MAPT 2267/4885POLB 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.